Spinal Cord Stimulation for Intractable Chronic Lower Abdominal Neuropathic Pain Caused by Endometriosis

Endometriosis Clinical Trial

Official title:

Spinal Cord Stimulation for Intractable Chronic Lower Abdominal Neuropathic Pain Caused by Endometriosis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05558540
• Other study ID #: NL76287.018.21
• Status: Not yet recruiting
• Phase: N/A
• Start date: October 1, 2022
• Est. completion date: June 1, 2024

Study information

• Verified date: September 2022
• Source: Amsterdam UMC, location VUmc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Endometriosis is a chronic, inflammatory disease where endometrium-like tissue is present outside the uterus. Nerve cells in the proximity of this tissue express cytokine receptors causing a signaling cascade. This results in active cross-talk between endometriosis and nerves, causing pelvic pain. Other symptoms associated with endometriosis are cyclical such as dysmenorrhea and dysuria, and non-cyclical such as dyspareunia. Despite adequate disease management, women can still experience endometriosis-related pain. A recent development proven to be efficient in treatment of neuropathic pain, is Spinal Cord Stimulation (SCS). It is also thought to be effective in the treatment of visceral pain. Several studies found Spinal Cord Stimulation (SCS) to be effective in the reduction of endometriosis-related pelvic pain. However, scientific evidence on the efficacy of SCS in visceral pain is limited.

Description:

Endometriosis is an estrogen-dependent gynaecologicalcondition characterized by the presence and growth of ectopic endometrial tissue. This tissue stimulates the infiltration of immune cells such as macrophages andmast cells into the peritoneal cavity. Both the immune cells and the endometriotic tissue secrete cytokines which create an inflammatory microenvironment. Nerve cells located in the proximity of endometriosis lesions express cytokine receptors which stimulate a cascade of signalling kinases within the nerve. This results in an active cross-talk between endometriosis and nerves causing endometriosis associated pain.

Because of the chronic nature of endometriosis, treatment can be challenging difficult. It consists of three pillars: hormonal therapy, surgery and conventional pain management. Despite adequate disease management, women with endometriosis can still experience endometriosis-associated chronic pelvic pain. This might suggest that the pathology was either an incidental finding, or that other mechanisms continue to generate pain without the need for a peripheral input. One study proposed that central sensitization may be involved mechanistically in the development and maintenance of endometriosis-related pain. The hypothesis was that persistent nociceptive input from endometriotic tissues might result in increased responsiveness among dorsal horn neurons processing input from the affected viscera and pelvic tissues [1].

When standard endometriosis treatment is insufficient in the suppression of endometriosis-related pelvic pain, spinal cord stimulation (SCS), an accepted treatment option for neuropathic pain, could be a potential treatment.This hypothesis was substantiated by several (case) studies. However, they stated that studies on SCS for treatment of visceral pain is limited and made a call for action to broaden this knowledge

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 15
• Est. completion date: June 1, 2024
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Premenopausal woman aged = 18 years

• Patients with endometriosis/ adenomyosis confirmed at surgery macroscopically and without options for further surgical treatment.

• Patients with at least one of the endometriosis related pain symptoms: dysmenorrhea, pelvic pain or dyspareunia. With a mean pain NRS of at least 5 (scale 0-10).

• The pain complaints are therapy resistant (including hormonal, medical and/or surgical options).

• Refractory pain; before neuromodulation patient has tried: Paracetamol, NSAIDs, Anti neuropathic pain therapy, TENS.

• The patient meets all the inclusion criteria for the implantation of a neurostimulation system as typically utilized in the study center.

• Neurologic exam without marked motor deficit.

• Subject has been screened by a multi-disciplinary panel including a psychologist and deemed suitable for implantation

• Subject is able and willing to comply with the follow-up schedule and protocol

• Subject is able to provide written informed consent

Exclusion Criteria:

• Female subject of childbearing potential is pregnant/nursing or plans to become pregnant during the course of the study.

• The presence of malignancy

• Subject currently has an active implantable device including ICD, pacemaker, spinal cord stimulator or intrathecal drug pump

• Subject is unable to operate the device

• Previous Neurostimulation therapy

Related Conditions & MeSH terms

• Endometriosis
• Neuralgia

Intervention

Device:
• spinal cord stimulator
By continuous electrical stimulation of the nerve causing endometriosis-related pain, painful inputs to the spinal cord and brain can be reduced or even eliminated. The electrical stimulation is performed by the spinal cord stimulator (SCS).

Locations

Country	Name	City	State
Netherlands	Amsterdam UMC, location VUmc	Amsterdam	Noord Holland

Sponsors (2)

Lead Sponsor	Collaborator
Prof. Velja Mijatovic	Boston Scientific Group

Country where clinical trial is conducted

Netherlands, 

References & Publications (1)

Bajaj P, Bajaj P, Madsen H, Arendt-Nielsen L. Endometriosis is associated with central sensitization: a psychophysical controlled study. J Pain. 2003 Sep;4(7):372-80. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in pain severity at 6 month follow-up	An aimed pain reduction of at least 30% or 2 points reduction in mean NRS pain score (0-10). This is measured using a pain diary.	6 months
Secondary	Change in Mean pain from baseline until 12 month follow-up	Measured using a pain diary, women report their pain score expressed with the Numeric rating scale (NRS) pain scores) 3 times a day for 3 days at baseline, 3-and 12-months post implant.	12 months
Secondary	Patient's global impression of change	Measured using the PGIC questionnaire. Dichotomous (better or improved versus not better or improved) at baseline,3-6-and 12-months post implant.	12 months
Secondary	Change in quality of life	Measured using the EHP-30 questionnaire at baseline, 3-6-and 12-months post implant. Each scale was transformed on a range from 0 to 100. A score of "0" stands for best possible health status. A score of "100" stands for worst possible health status.	12 months
Secondary	Change in quality of life	Measured using the SF-36 questionnaire at baseline, 3-6-and 12-months post implant. Scores are divided between 8 domains and calculated. They range from 0 to 100, and are compiled as a percentage. The higher the score, the more favorable the health state.	12 months
Secondary	Change in fatigue	Measured using the shortened fatigue questionnaire (SFQ) at baseline, 3-6-and 12-months post implant. Scores can range between 4 and 28. The higher the score, the more severe the fatique.	12 months
Secondary	Change in Pain Catastrophizing Scale	Measured using the PCS questionnaire. Measured at baseline, 3-6-and 12-months post implant. A score between 0 and 52 can be calculated. The higher the score, the more severe the patient catastrophizes her pain.	12 months
Secondary	Change in Central Sensitization Inventory	Measured using the CSI questionnaire. Measured at baseline, 3-6-and 12-months post implant. A score between 0 and 100 can be calculated. A score between 0-29 stands for subclinical central sensitization syndrome (CSS). A score between 30 and 39 for mild SCC. A score between 40 and 49 for moderate SCC. A score between 50 and 59 for severe SCC. A score between 60-100 for extreme SCC.	12 months
Secondary	Change in pain medication use	Assessed using a questionnaire. Women are asked on their possible use of pain medication at baseline, 3-month, 6-month and 12-month follow up. Use of pain medication is compared between the follow-up moments.	12 months
Secondary	Lost working days	Measured using the EHP-30 at baseline and at 6 months post implant. Asked using part A of the modular questionnaire. A score between 0 and 100 can be calculated. The higher the score, the higher the impact of endometriosis on working life.	6 months